Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Company Overview - Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, including obesity [3] - The company utilizes its Compass™ platform to pursue genetically validated targets, integrating variant discovery and functionalization to advance small molecule programs with first- or best-in-class potential [3] Pipeline Development - Maze's leading pipeline candidates include MZE829, a dual-mechanism APOL1 inhibitor currently in Phase 2 development for APOL1-mediated kidney disease (AMKD) [3] - Another candidate, MZE782, is a SLC6A19 inhibitor advancing to Phase 2, with potential applications in treating both phenylketonuria (PKU) and chronic kidney disease (CKD) [3] Upcoming Events - Jason Coloma, Ph.D., the CEO of Maze Therapeutics, is scheduled to present at the TD Cowen 46 Annual Health Care Conference on March 4, 2026, at 10:30 a.m. ET [1] - A live webcast of the presentation will be available on the company's website and archived for 60 days [2]